LTRN News & Events

Lantern Pharma unveiled the next phase of its development roadmap for withZeta.ai, the company's multi-agentic A.I. co-scientist platform for oncology research and drug discovery. Future development plans for release in the coming year include three major capability tracks: ZetaSwarm, an autonomous multi-agent swarm intelligence layer; ZetaOmics, a real-time computational biology and multi-omic analytics toolkit that extends withZeta.ai's existing production foundation of 34 bioinformatics, chemoinformatic, and clinical research tools; and a new suite of enterprise-grade platform features designed for institutional and commercial deployment. The roadmap brings together two threads that have been advancing in parallel across AI for biomedicine into a single, integrated research environment. ZetaSwarm and ZetaOmics are intended to make withZeta.ai one of the few platforms in oncology AI that operates fluently in both domains, with shared infrastructure, shared authentication, and a unified audit trail. With ZetaSwarm, ZetaOmics, and enterprise capabilities, withZeta.ai is expected to deepen its role as both a hyper-productivity layer for Lantern's internal R&D focused on novel drug development and as a standalone commercial AI platform offering for the broader oncology research community.

Lantern Pharma announced the expansion of predictBBB.ai into a Large Quantitative Model- a real-time quantitative intelligence engine now accessible to any researcher or drug development team, anywhere in the world, through a single browser interface. The company said, "For the first time, pharmaceutical scientists and medicinal chemists can access a unified, benchmark-validated LQM - not as a batch software installation, not as a siloed cheminformatics tool - but as an on-demand molecular intelligence engine delivered as a web service. By submitting a single SMILES string, users receive a comprehensive, 360-degree developability profile of any small molecule in seconds: a capability that previously required hours of computation across multiple platforms and specialized bioinformatics personnel to integrate - removing the computational barriers that have historically limited rigorous molecular characterization to large, well-resourced pharmaceutical organizations, and making that same analytical power available to biotech innovators, academic drug hunters, and rare disease programs worldwide."

Lantern Pharma has scheduled a Type C meeting with the U.S. Food and Drug Administration for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who have progressed following any TKI-based treatment- a population carrying a particularly poor prognosis and limited remaining therapeutic options. Lantern is seeking the FDA's scientific guidance to sharpen the trial design around the patients most likely to benefit, and to pursue the most rigorous and efficient development path possible.Preliminary clinical data from the HARMONIC trial, with a data cutoff of April 13, 2026, have revealed a differentiated and consistent progression-free survival profile for LP-300 in patients harboring the EGFR Exon 21 L858R mutation - accounting for approximately 40% of all EGFR-mutant NSCLC cases globally, and a subgroup with a notably inferior prognosis following frontline TKI therapy compared with Exon 19 deletion patients. Among L858R patients in HARMONIC, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients that had only 4 doses or cycles of LP-300. These outcomes were observed in patients who had already progressed on tyrosine kinase inhibitor therapy - a setting where prognosis is particularly challenging and where treatment tolerability is a critical consideration. The upper confidence interval for mPFS for the L858R patient group remains not calculable at the time of analysis, suggesting that a meaningful proportion of patients may be achieving disease control that extends substantially beyond the reported median. The Hazard Ratio observations to date for the L858R patient group are also encouraging.